30th Edition of Oncology Summit | 04-06 December 2025 | Dubai, United Arab Emirates (Hybird)
31st Edition of Oncology Summit | 19-22 February 2026 | Amsterdam, Netherlands
32nd Edition of Oncology Summit | 16-19 April 2026 | London, United Kingdom
Conference logo
“Smoking is the main cause of lung cancer in almost 70% of the cases”- Dr. Sanyo Dsouza, Consultant- Medical Oncology Lung cancer has very common symptoms such as cough and breathing difficulties, making it hard to detect as people do not get these symptoms checked out immediately. Early detection is key in beating cancer and thus it is essential to be aware of the symptoms. Watch more here! visit: https://x-i.me/srimonco
International Conference on Oncology and Cancer Research -Visit :https://x-i.me/oan
This speech was delivered by Assist Prof Dr. LAILA JARAGH-ALHADAD , Kuwait University , Kuwait during the International Conference on Oncology and Cancer Research that was Organised by Pencis at on 12-14 -Dec -2021
Dr. Laila Jaragh-Alhadad research’s interest focuses on design, synthesis, characterize & biologically evaluate anticancer agents that target small molecules which have essential roles elevating in cancer cell division. First project area is targeting both HSP27 & HER2 proteins with inhibitors in several human cancer cell lines to improve the ADME profile. HSP27 and HER2 proteins are both attractive molecular targets for cancer therapy because of their cellular functions, which are proportionally up and down regulated in cancer cells. The goal is to synthesize a library of compounds targeting HSP27 and stabilize HER2 through HER2 pathway and choose the best drug candidate for further in-vivo evaluations. The development of this series of anticancer agents may overcome the chemotherapy drug resistance and improve the survival of cancer patients. Second project area is the strategies and techniques for drug delivery to accumulate a certain amount of the drug to some part of the body relative to others. The goal is to encapsulate the drug candidate into nanoparticles such as low-density lipoprotein, liposomes & cholesterol conjugates to mimic the natural lipid metabolic pathway to reach the center of cancer cells, to improve the drug efficacy, delivery and minimizing the side effects.
New fields under our focus is targeting tubulin protein that has important cellular roles in cell proliferation. Other cancer fields are Angiogenesis I, II and photoelectric Agents.
Benefit from the drugs that are already in the market and change their skeleton by applying the structure activity relationship (SAR) to change them to anticancer drugs useful for cancer patient’s treatment. Congratulation for Best Research Award by pencis
This speech was delivered by Assoc Prof Dr .Juliana Inaba ,Universidade Estadual de Ponta Grossa,Brazil , during the International Conference on Oncology and Cancer Research that was Organised by Pencis at Online Virtual Conference on 18-20 July 2021
Samiha Ahmed El-Sebaey is an Egyptian Lecturer of Pharmaceutical Organic Chemistry at faculty of pharmacy (Girls), Al-Azhar University, Cairo, Egypt. She received her M.Sc. degree in 2013 and a Ph.D. degree in 2016 after receiving her excellent with honors B.Sc. in 2008 from the Faculty of Pharmacy at Al-Azhar University, Egypt. She is interested in pharmaceutical chemistry, drug design, and biological activity, especially antitumor and antiviral activities. Her main areas of research interest include the design, molecular docking study, and synthesis of novel heterocyclic compounds through various synthetic strategies, attempting the unique techniques in order to obtain eco-friendly, efficient, and time-saving procedures at the forefront of the discovery of active compounds that have high biological activity. Over the years, she has taught many courses in pharmaceutical organic chemistry as well as more general courses. She has presented papers at conferences both at home and abroad, and she has published articles and reports in various journals. congratulation Best Researcher Award by Pencis